Pharmacoeconomic evaluation of iruplinalkib therapy for advanced <italic style="font-style: italic">ALK</italic>-positive non-small cell lung cancer

WANG Hong; LI Haonan; ZHANG Hui; LIU Yuhang; XU Yeyou; WENG Kaiyuan

doi:10.6039/j.issn.1001-0408.2025.08.09

您当前的位置：

首页 >

文章列表页 >

Pharmacoeconomic evaluation of iruplinalkib therapy for advanced ALK-positive non-small cell lung cancer

更新时间：2025-09-23

- Pharmacoeconomic evaluation of iruplinalkib therapy for advanced ALK-positive non-small cell lung cancer
- ZHONGGUO YAOFANG Vol. 36, Issue 8, Pages: 945-950(2025)
- 作者机构：
  
  1.广东药科大学医药商学院，广州　510006
  2.北京大学药学院，北京　100191
  3.北京大学医药管理国际研究中心，北京　100191
  4.广东药科大学卫生经济与健康促进研究中心，广州　510006
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.08.09
  CLC： R956
- Received：11 June 2024，
  
  Revised：2025-03-03，
  
  Accepted：04 March 2025，
  
  Published：30 April 2025
- 稿件说明：
移动端阅览
汪虹,李浩楠,张慧,等.伊鲁阿克治疗ALK阳性晚期NSCLC的药物经济学评价 [J].中国药房,2025,36(08):945-950.

WANG Hong,LI Haonan,ZHANG Hui,et al.Pharmacoeconomic evaluation of iruplinalkib therapy for advanced ALK-positive non-small cell lung cancer[J].ZHONGGUO YAOFANG,2025,36(08):945-950.
汪虹,李浩楠,张慧,等.伊鲁阿克治疗ALK阳性晚期NSCLC的药物经济学评价 [J].中国药房,2025,36(08):945-950. DOI： 10.6039/j.issn.1001-0408.2025.08.09.

WANG Hong,LI Haonan,ZHANG Hui,et al.Pharmacoeconomic evaluation of iruplinalkib therapy for advanced ALK-positive non-small cell lung cancer[J].ZHONGGUO YAOFANG,2025,36(08):945-950. DOI： 10.6039/j.issn.1001-0408.2025.08.09.

摘要

目的

从我国卫生体系角度出发，评价伊鲁阿克用于

ALK

阳性且之前没有接受过

ALK-

酪氨酸激酶抑制剂（TKIs）治疗的非小细胞肺癌（NSCLC）患者的经济性。

方法

从中国卫生体系角度出发，基于INSPIRE研究，建立三状态的分区生存模型模拟疾病发展进程，设定模拟周期为3周，研究时限为15年，贴现率为5.0%，比较伊鲁阿克和克唑替尼两种方案治疗

ALK

阳性的晚期NSCLC的总成本、质量调整生命年（QALY）和增量成本-效果比（ICER）；以1～3倍我国2023年人均国内生产总值（GDP）（89 358～268 074元）作为意愿支付（WTP）阈值比较两种方案的经济性，并采用情境分析（改变生存曲线分布、效用值）和敏感性分析来验证模型的稳定性。

结果

与克唑替尼方案相比，伊鲁阿克方案的ICER为194 412.74元/QALY，小于3倍我国2023年人均GDP（268 074元）的WTP阈值；改变生存曲线分布情境下的结果与基础分析结果一致，但提高疾病进展状态的效用值后，ICER大于WTP阈值，伊鲁阿克方案将不再具有经济性优势。单因素敏感性分析结果表明，伊鲁阿克的成本、疾病进展状态效用值等对ICER的影响较大。概率敏感性分析表明基础分析结果稳健。

结论

从我国卫生体系角度出发，与克唑替尼方案相比，伊鲁阿克治疗

ALK

阳性且之前没有接受过

ALK

-TKIs治疗的NSCLC具有经济性。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of iruplinalkib for

ALK

-positive non-small cell lung cancer （NSCLC） patients who had not previously received

ALK

-tyrosine kinase inhibitors （TKIs） from the perspective of the Chinese healthcare system.

METHODS

Based on the INSPIRE clinical trial， a three-health state partitioned survival model was developed to simulate the progression of disease， with model cycle of 3 weeks and a life-year time range of 15 years； the discount rate was 5%. For the treatment of

ALK

-positive advanced NSCLC， total cost， quality-adjusted life year （QALY）， and incremental cost-effectiveness ratio （ICER） were compared between iruplinalkib and crizotinib； using 1-3 times China’s per capita gross domestic product （GDP）（89 358-268 074 yuan） in 2023 as the willingness-to-pay （WTP） threshold， the cost-effectiveness of two regimens were compared. The sensitivity analysis and scenario analysis （altering the distribution of survival curves， utility values） were conducted to assess model robustness.

RESULTS

Compared with the crizotinib regimen， the ICER for the iruplinalkib regimen was 194 412.74 yuan/QALY， which was below the WTP threshold of three times China’s per capita GDP in 2023 （268 074 yuan）. The results under the scenario of altering the survival curve distribution were consistent with the base case analysis. However， after increasing the utility value of the disease progression state， the ICER exceeded the WTP threshold， and iruplinalkib no longer had a cost-effective advantage. The results of the one-way sensitivity analysis indicated that the cost of iruplinalkib and the utility values of disease progression states had a significant impact on the ICER. The probabilistic sensitivity analysis confirmed the robustness of the base case analysis results.

CONCLUSIONS

From the perspective of China’s healthcare system， compared with crizotinib regimen， the therapy with iruplinalkib is cost-effective for

ALK

-positive NSCLC patients who have not previously received

ALK

-TKIs.

关键词

Keywords

references

中国医疗保健国际交流促进会肿瘤内科学分会，中国医师协会肿瘤医师分会 . Ⅳ期原发性肺癌中国治疗指南： 2024版 [J ] . 中华肿瘤杂志， 2024 ， 46 （ 7 ）： 595 - 636 .

中国非小细胞肺癌ALK检测模式真实世界多中心研究专家组，中华医学会病理学分会分子病理学组 . 中国非小细胞肺癌ALK检测临床实践专家共识 [J ] . 中华病理学杂志， 2019 ， 48 （ 12 ）： 913 - 920 .

中国医疗保健国际交流促进会肿瘤内科学分会，中国医师协会肿瘤医师分会 . 伊鲁阿克治疗间变性淋巴瘤激酶融合基因阳性局部晚期或转移性非小细胞肺癌中国专家共识： 2024版 [J ] . 中华肿瘤杂志， 2024 ， 46 （ 3 ）： 189 - 205 .

HARATAKE N ， TOYOKAWA G ， SETO T ， et al . The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance [J ] . Expert Rev Anticancer Ther ， 2021 ， 21 （ 9 ）： 975 - 988 .

SHI Y K ， CHEN J H ， YANG R X ， et al . Iruplinalkib（WX-0593）versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive NSCLC：interim analysis of a randomized，open-label，phase 3 study（INSPIRE） [J ] . J Thorac Oncol ， 2024 ， 19 （ 6 ）： 912 - 927 .

谭婧，熊益权，黄诗尧，等 . 用于药品临床价值和经济价值评价的真实世界数据关键技术考量 [J ] . 中国循证医学杂志， 2024 ， 24 （ 5 ）： 516 - 522 .

PICHON-RIVIERE A ， DRUMMOND M ， PALACIOS A ， et al . Determining the efficiency path to universal health coverage：cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures [J ] . Lancet Glob Health ， 2023 ， 11 （ 6 ）： e833 - e842 .

刘国恩 . 中国药物经济学评价指南导读：2022 [M ] . 北京：中国市场出版社， 2022 ： 25 - 27 .

石丰豪，商叶，芮明军，等 . R语言survHE程序包在卫生经济学评价中的应用 [J ] . 中国卫生经济， 2020 ， 39 （ 9 ）： 9 - 14 .

BULLEMENT A ， MENG Y ， COOPER M ， et al . A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence：how did the initial best estimate compare to trial data subsequently made available? [J ] . J Med Econ ， 2019 ， 22 （ 3 ）： 205 - 214 .

LU S ， YE M ， DING L ， et al . Cost-effectiveness of gefitinib，icotinib，and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China [J ] . Oncotarget ， 2017 ， 8 （ 6 ）： 9996 - 10006 .

DAI Z ， XU J ， CHANG F ， et al . The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China [J ] . Front Public Health ， 2024 ， 12 ： 1333487 .

GUAN H J ， LIU G ， XIE F ， et al . Cost-effectiveness of osimertinib as a second-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer in China [J ] . Clin Ther ， 2019 ， 41 （ 11 ）： 2308 - 2320 .

LIU W ， HUO G ， CHEN P . First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer：a cost-effectiveness analysis in the United States [J ] . Front Pharmacol ， 2023 ， 14 ： 1163381 .

NAFEES B ， LLOYD A J ， DEWILDE S ， et al . Health state utilities in non-small cell lung cancer：an international study [J ] . Asia Pac J Clin Oncol ， 2017 ， 13 （ 5 ）： e195 - e203 .

SHEN Y ， WU B ， WANG X ， et al . Health state utilities in patients with advanced non-small-cell lung cancer in China [J ] . J Comp Eff Res ， 2018 ， 7 （ 5 ）： 443 - 452 .

LIU M ， ZHANG L ， HUANG Q ， et al . Cost-effectiveness analysis of ceritinib and alectinib versus crizotinib in the treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer [J ] . Cancer Manag Res ， 2019 ， 11 ： 9195 - 9202 .

孙蕾，周大创，陈平钰，等 . 恩沙替尼一线治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌的药物经济学评价 [J ] . 中国药房， 2022 ， 33 （ 12 ）： 1479 - 1484 .

ALLEMANI C ， MATSUDA T ， DI CARLO V ， et al . Global surveillance of trends in cancer survival 2000-14（CONCORD-3）：analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries [J ] . Lancet ， 2018 ， 391 （ 10125 ）： 1023 - 1075 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Cost-utility analysis of sugemalimab combined with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma with high PD-L1 expression

Pharmacoeconomic evaluation of sugemalimab consolidation therapy for stage Ⅲ non-small cell lung cancer

Cost-utility analysis of sacituzumab govitecan versus single-agent chemotherapy in the treatment of HR+/HER2－ advanced metastatic breast cancer

Cost-utility analysis of benmelstobart plus anlotinib and chemotherapy as first-line treatment for extensive-stage small cell lung cancer

Pharmacoeconomic evaluation of finerenone combined with standard treatment regimen in the treatment of diabetic nephropathy

Related Author

CHEN Qiuping

SUN Quan

SHEN Zhengnan

TANG Congying

LIU Jibin

LI Baixue

SU Hang

WANG Lin

Related Institution

College of Basic Medicine， Chengdu University of TCM

Hainan Zhongwei Institute of Health Economy Development

Dept. of Infectious Disease， College of Clinical Medicine， Chengdu University of TCM

School of International Pharmaceutical Business， China Pharmaceutical University

Dept. of Pharmacy， the Second Affiliated Hospital of Wannan Medical College

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Pharmacoeconomic evaluation of iruplinalkib therapy for advanced ALK-positive non-small cell lung cancer

DOI：10.6039/j.issn.1001-0408.2025.08.09

摘要

Abstract

关键词

Keywords

references